The native capsular polysaccharide of type III group B Streptococcus elicits a specific antibody response in only 60% of nonimmune human subjects. To enhance the immunogenicity of this polysaccharide, we coupled the type III polysaccharide to tetanus toxoid. Prior to coupling, aldehyde groups were introduced on the polysaccharide by controlled periodate oxidation, resulting in the conversion of 25% of the sialic acid residues of the polysaccharide to residues of the 8-carbon analogue of sialic acid, 5-acetamido-3,5-dideoxy-D-galactosyloctulosonic acid. Tetanus toxoid was conjugated to the polysaccharide by reductive amination, via the free aldehyde groups present on the partially oxidized sialic acid residues. Rabbits vaccinated with the conjugate vaccine produced IgG antibodies that reacted with the native type III group B streptococcal polysaccharide (3/3 rabbits), while rabbits immunized with the unconjugated type III polysaccharide failed to respond (0/3 rabbits). Sera from animals receiving conjugate vaccine opsonized type III group B streptococci for phagocytic killing by human peripheral blood leukocytes, and protected mice against lethal challenge with live type III group B streptococci. The results suggest that this method of conjugation to a carrier protein may be a useful strategy to improve the immunogenicity of the type III group B Streptococcus polysaccharide in human sub-
Introduction
Group B Streptococcus (GBS)' is a major cause of neonatal sepsis and meningitis in the United States, with a nationwide attack rate estimated at 2-3 per 1,000 live births (1) (2) (3) . Despite advances in diagnosis and improved supportive care, neonatal 1 . Abbreviations used in this paper: GBS, group B Streptococcus; GC-MS, gas chromatography-mass spectrometry; NMR, nuclear magnetic resonance spectroscopy.
GBS infection still carries a 10-20% mortality, and an estimated 30-50% incidence of serious long term neurologic sequelae among survivors of GBS meningitis (4) (5) (6) . Organisms of capsular type III are most prevalent among GBS strains causing invasive neonatal disease, accounting for approximately 60%Yo of all GBS isolates from neonatal sepsis and meningitis cases (2, 7) . A large body of experimental evidence has indicated that one of the major determinants of immunity to GBS infection is antibody directed against the type-specific capsular polysaccharide of the organism. Baker and Kasper demonstrated that human infants with type III GBS sepsis and meningitis uniformly had low or undetectable levels of anticapsular antibodies (8) . As IgG class antibodies cross the placenta and could achieve protective levels in the fetus before delivery, immunization of women before or during pregnancy has been proposed as a strategy to prevent neonatal GBS infection (9, 10) . Purified preparations ofthree of the four major capsular polysaccharides (la, II, III) have been given as experimental vaccines both to animals and to human volunteers (9) (10) (11) (12) (13) . While maternal vaccination appears to be a promising approach for preventing neonatal GBS disease, the native type III polysaccharide vaccine elicits a specific antibody response in only 60% of nonimmune recipients (10, 12, 13) .
Conjugation to a carrier protein is a strategy which has been used successfully to enhance the immunogenicity of several polysaccharide antigens, including such bacterial capsular polysaccharides as the type b capsule of Haemophilus influenzae, groups A and C meningococcus, and others (14) (15) (16) . A variety of coupling methods have been utilized to link polysaccharides to protein carriers directly or via a synthetic spacer molecule (17) . In some cases the efficiency of the coupling reaction has been increased by the introduction of functional groups at specific or random sites on the polysaccharide. Such modifications of the carbohydrate, however, may alter the structure of the polysaccharide sufficiently to affect epitope expression, in which case the polysaccharide-protein conjugate may not elicit antibodies reactive with the native antigen. Antibodies directed against the GBS type III capsular polysaccharide appear to recognize a conformational epitope. The epitope is influenced both by the charged sialic acid residues present as side chain termini of the polysaccharide, and by the polymeric state of the polysaccharide (18) (19) (20) Mr. Analysis of this material by gas chromatography-mass spectrometry (GC-MS) after conversion of the component sugars to alditol acetates, and by 'H-nuclear magnetic resonance spectroscopy ('H-NMR), confirmed the native type III polysaccharide structure and the absence of contaminating group B polysaccharide (19) .
Periodate oxidation oftype III polysaccharide. GBS type III polysaccharide (16 mg) was incubated with 4 uM of sodium periodate in 1.6 ml ofwater, in the dark, at 230C for 1 h. Ethylene glycol was added to consume any residual periodate, the mixture was dialyzed against water, and lyophilized. Degree of oxidation of the sialic acid residues was assessed by GC-MS oftrimethylsilyl derivatives: a 1-mg sample of the oxidized polysaccharide was treated with sodium borohydride, 10 mg in 0.5 ml water, at 230C for 1 h, then deionized over Rexyn 10 1(H) resin (Fisher Scientific Co., Fair Lawn, NJ), and evaporated three times on a rotary evaporator with 5-ml amounts of methanol. Sialic acid residues and their oxidized derivatives were hydrolyzed from the polysaccharide and converted to methyl esters/methyl glycosides by treatment with 2 N methanolic HCl, 1 ml, at 800C for 2 h. HCI was removed by evaporation with methanol, and trimethylsilyl derivatives were prepared, as described (23) . Analysis of this sample by GC-MS was carried out as described (24) .
Purification of tetanus toxoid. Tetanus toxoid (Institute Armand
Frappier, Montreal, Canada) was purified by gel filtration chromatography before use. 15 ml of a liquid preparation containing 1 mg/ml protein nitrogen was loaded onto a 2.6 X 90 cm column of Ultragel ACA44 equilibrated in PBS and eluted with the same buffer. Protein eluted from the column in two peaks: the earlier eluting peak contained polymerized toxoid, and the later eluting peak, corresponding to -150,000 Mr, contained tetanus toxoid monomer. Fractions corresponding to the later (monomer) peak were pooled, dialyzed against water, and lyophilized.
Coupling of type III polysaccharide to tetanus toxoid. Periodatetreated type III polysaccharide (11 mg) and purified tetanus toxoid monomer (11 mg) were dissolved in 0.1 M sodium bicarbonate, -pH 8.1. Sodium cyanoborohydride (20 mg) was added, and the mixture was incubated at 37°C for 10 d. The progress of the conjugation was monitored by removing aliquots at various time points for analysis by fast performance liquid chromatography (FPLC), using a Superose 6, HR 10/30 column (Pharmacia Fine Chemicals, Div. of Pharmacia, Inc., Piscataway, NJ), with PBS as eluant at a flow rate of 0.5 ml/min. Conjugation of polysaccharide to tetanus toxoid was indicated by a progressive increase in a broad peak (monitored by measurement of UV absorbance at 214 nm) eluting soon after the void volume of this column. After conjugation was complete, sodium borohydride (10 mg) was added to the reaction mixture to reduce any remaining free aldehyde groups. The conjugate was purified by passage over a 1.6 X 85 cm column of Biogel A, 0.5 M (Bio-Rad Laboratories, Richmond, CA), equilibrated in PBS, and eluted with the same buffer. Fractions corresponding to the void volume peak were pooled, dialyzed against water, and Iyophilized.
Chemical analysis of the conjugate. Carbohydrate content was measured by the phenol-sulfuric acid method, using the native type III polysaccharide as a standard (25) . Protein content was measured by the method of Lowry et al., using bovine serum albumin as a standard (26) . Sialic acid content was measured by the resorcinol method, using sialic acid as a standard (27 Measurement of antibodies against type III GBS polysaccharide. Antibodies against the native type III GBS polysaccharide were measured by ELISA. Native type III polysaccharide was coupled to poly-Llysine and coated onto 96-well flat bottom plastic plates at a concentration of I gg/ml, as previously described (28) . Test serum at several dilutions was added, and subsequent steps of addition of alkaline phosphatase coupled antirabbit IgG and substrate carried out as described previously (29) . Each assay was standardized using a reference serum (raised against formalinized whole type III GBS) on the same plate. Plates were read when duplicate wells developed with the reference serum at a dilution of 1:80,000 reached absorbance at 405 nm = 0.5. Antibody titer was defined as the reciprocal of the highest serum dilution giving absorbance at 405 nm > 0.3.
Opsonophagocytic assays. Opsonophagocytic assays were performed essentially as described by Baltimore et al. (29) . Early log phase organisms of type III GBS strain M78 1 (4 X 106 CFU) were incubated with 3 X 106 human peripheral blood leukocytes in 0.5 ml of Eagle's minimal essential medium. Each assay contained, in addition, 10% human serum (previously absorbed with GBS type III organisms and stored at -800C to preserve complement activity) and the rabbit serum to be tested, at a final concentration of 1% vol/vol (i.e., 1:100 dilution). Aliquots were removed, diluted in sterile water, and spread on blood agar plates for quantitative culture at time zero and after 1 h of endover-end rotation at 370C.
Mouse protection assay. Female CD-1 mice (Charles River Breeding Laboratories, Inc., Wilmington, MA) weighing 20-25 g were given a single intraperitoneal injection of undiluted antiserum or antiserum diluted in PBS in a total volume of 0.2 ml. 24 h later, the mice were challenged with an LD90 dose (6.6 X I07 CFU) of strain M78 1, administered by intraperitoneal injection in a total volume of 1 ml of Todd Hewitt broth. Dead animals were removed from the cages at 24-h intervals, and the overall mortality for each group was assessed at 3 d after challenge.
Results
Preparation ofthe conjugate vaccine. The presence of a(2 --3)
linked sialic acid residues as side chain termini provides a unique site for introduction of free aldehyde groups on the GI3S type III polysaccharide, without disrupting the native epitope. Controlled periodate oxidation results'in cleavage of the polyhydroxylated tail of sialic acid, leaving the 8-carbon analogue (5-acetamido-3,5-dideoxy-D-galactosyloctulosonic acid) or 7-carbon analogue (5-acetamido-3,5-dideoxy-D-galactosylheptulosonic acid), with a free terminal aldehyde group at the site of periodate cleavage (30) . Immunochemical and NMR studies of the type III GBS polysaccharide have indicated that oxidation of the sialic acid residues of the polysaccharide does not alter the antigenicity (i.e., reactivity with antibodies raised against organisms bearing the native polysaccharide) or physical conformation of the polysaccharide (18) .
As this modification appears not to alter the antibody binding characteristics ofthe native epitope, we utilized limited periodate oxidation to cleave carbon 9 from 25% of the sialic acid residues of the type III polysaccharide, leaving a free aldehyde at the carbon-8 position of the oxidized residues available as sites for coupling to a carrier protein by reductive amination (Fig. 1) . The periodate-treated polysaccharide was analyzed by GC-MS after reduction, methanolysis, and preparation of trimethylsilyl derivatives of the native or partially oxidized sialic acid residues (Fig. 2) . The signals representing the native sialic acid (C9) derivative and the partially oxidized 8-carbon (C8) derivative had relative abundances of 75.5% and 24.5%, respectively, confirming that -75% of the sialic acid residues remained in the native state, while 25% had been converted to the C8 analogue (Fig. 2) . Under these conditions, further oxidation to the C7 analogue did not occur to an extent detectable by GC-MS analysis. The partially oxidized polysaccharide was covalently linked to tetanus toxoid by reductive amination using sodium cyanoborohydride. The progress ofthe conjugation was monitored by FPLC analysis, on a Superose 6 column, of small aliquots of the reaction mixture. Polysaccharide-tetanus toxoid conjugate eluted from the column'in a broad peak that began at 11 min, just after the void volume, and extended into the beginning of a second peak (Fig. 3) . The (Fig. 3) . After without Freund's adjuvant. Peak antibody titers of these three rabbits were 400, 1,600, and 1,600, reached at day 34, 34, and 55, respectively. Thus, even in the absence of adjuvant, the conjugate elicited specific IgG antibodies, while the unconjugated polysaccharide was nonimmunogenic. Sera from rabbits immunized without adjuvant were not used in opsonophagocytic assays or mouse protection studies. Opsonic capacity of vaccine-induced antibodies. We tested the ability of antiserum from rabbits vaccinated with either the native GBS type III polysaccharide or the polysaccharide-protein conjugate vaccine to opsonize type III GBS organisms. Incubation of type III GBS with human peripheral blood leukocytes, a complement source, and sera from rabbits vaccinated with the conjugate vaccine resulted in a 1.8-2.0 log decrease in CFU after 1 h, compared with the input inoculum (Table II) . The same degree of killing was observed when a purified IgG fraction, prepared by Protein A-Sepharose affinity chromatography ofconjugate-induced immune serum, was substituted for whole serum (data not shown). Neither preimmune sera from rabbits receiving the conjugate vaccine, nor postvaccination sera from animals receiving the native polysaccharide produced more than a 0.15 log reduction in CFU, under the same conditions (Table II) . Mouse protection by vaccine-induced antibodies. To further establish the functional capacity of vaccine-induced antibodies, groups of mice were injected with pooled serum from rabbits vaccinated either with the native polysaccharide or with the conjugate vaccine. 24 h later, the mice were given an LD90 dose of live organisms of type III GBS strain M78 1. Neither preimmune serum from rabbits receiving the conjugate vaccine, nor postvaccination serum from rabbits receiving the native polysaccharide alone provided any protection, while postvaccination serum from rabbits receiving the conjugate vaccine was highly protective at both doses tested: 100% sur- (16) . In view of potential future use in human subjects, tetanus toxoid was used as the carrier protein as this preparation has an established record of safety for immunization of pregnant women (34) .
Immune defense against GBS, like that against other Gram positive bacteria, depends on clearance of the organisms by phagocytic leukocytes. Type III GBS isolates from infants with invasive GBS disease are generally resistant to phagocytic killing by peripheral blood leukocytes in the presence of nonimmune serum (29) . Antibodies directed against the type III capsular polysaccharide, in concert with serum complement, effectively opsonize type III GBS for phagocytic killing, in vitro (29) . The GBS type III polysaccharide-tetanus toxoid conjugate vaccine elicited high titered, functional, IgG class antibodies in rabbits. The isolated native type III polysaccharide was completely nonimmunogenic, while the conjugate vaccine elicited IgG class antibodies after a single dose. Moreover, the titer rose in all animals after each of two booster doses of conjugate vaccine given 3 and 6 wk after the first injection. The antibodies elicited by the conjugate opsonized type III GBS organisms for phagocytosis in vitro, and protected mice against lethal challenge with type III GBS organisms.
While characterization of the T cell dependency of various antigens has been done primarily in mice, the rabbit model may be a better predictor of the response of human subjects to a GBS conjugate vaccine. TI antigens such as bacterial polysaccharides classically elicit a weak, predominantly IgM antibody response in mice, which cannot be augmented further by booster vaccination. In contrast, rabbits, like 40% of adult humans, uniformly fail to develop any antibody response to vaccination with the native GBS type III polysaccharide. Our data on immunogenicity of the GBS type III conjugate vaccine in rabbits suggest that conjugation of the GBS type III polysaccharide to tetanus toxoid may greatly enhance the immunogenicity of this antigen in those human subjects who fail to respond to the native polysaccharide. These results establish the immunogenicity in animals of a conjugate vaccine against type III GBS, and provide a rationale for testing a vaccine of this design in human subjects.
